UBS O'Connor’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4,283,462
| Closed | -$457M | – | 319 |
|
|
2025
Q3 | $457M | Buy |
+4,283,462
| New | +$447M | 13.68% | 2 |
|
|
2025
Q2 | – | Sell |
-17,150
| Closed | -$1.09M | – | 459 |
|
|
2025
Q1 | $1.09M | Buy |
+17,150
| New | +$1.03M | 0.03% | 179 |
|
|
2024
Q4 | – | Sell |
-22,541
| Closed | -$846K | – | 582 |
|
|
2024
Q3 | $649K | Buy |
+22,541
| New | +$555K | 0.02% | 322 |
|
|
2024
Q2 | – | Sell |
-36,305
| Closed | -$530K | – | 638 |
|
|
2024
Q1 | $584K | Sell |
36,305
-12,228
| -25% | -$211K | 0.02% | 321 |
|
|
2023
Q4 | $965K | Sell |
48,533
-39,095
| -45% | -$577K | 0.03% | 274 |
|
|
2023
Q3 | $1.43M | Hold |
87,628
| – | – | 0.03% | 290 |
|
|
2023
Q2 | $1.85M | Sell |
87,628
-9,944
| -10% | -$212K | 0.04% | 311 |
|
|
2023
Q1 | $1.96M | Sell |
97,572
-31,354
| -24% | -$677K | 0.05% | 315 |
|
|
2022
Q4 | $3.37M | Buy |
128,926
+17,000
| +15% | +$226K | 0.06% | 292 |
|
|
2022
Q3 | $1.14M | Buy |
+111,926
| New | +$943K | 0.01% | 731 |
|
Other funds holding VRNA
UBS O'Connor's VRNA Position: Q4 2025 in Review
UBS O'Connor sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 4,283,462 shares — an estimated $457M sold.
UBS O'Connor first reported a position in VRNA in Q3 2022 and held it in 10 quarters. The position peaked at $457M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- UBS O'Connor reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- UBS O'Connor sold 4,283,462 Verona Pharma shares in Q4 2025, an estimated $457M.
- UBS O'Connor first reported a position in Verona Pharma in Q3 2022 and held it in 10 quarters.
- UBS O'Connor's Verona Pharma position peaked at $457M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.